Ultragenyx Pharma (RARE) Misses Q2 EPS by 2c
Ultragenyx Pharma (NASDAQ: RARE) reported Q2 EPS of ($1.46), $0.02 worse than the analyst estimate of ($1.44).
For earnings history and earnings-related data on Ultragenyx Pharma (RARE) click here.
Ultragenyx Pharma (NASDAQ: RARE) reported Q2 EPS of ($1.46), $0.02 worse than the analyst estimate of ($1.44).
For earnings history and earnings-related data on Ultragenyx Pharma (RARE) click here.